Literature DB >> 35437704

Ultrasound-targeted microbubble destruction-mediated silencing of FBXO11 suppresses development of pancreatic cancer.

Jing Xue1, Shengjiang Chen2, Dongfeng Ge3, Xiaozhi Yuan4.   

Abstract

Ultrasound-targeted microbubble destruction (UTMD) has been a promising noninvasive tool for organ- or tissue-specific gene or drug delivery. This study aimed to explore the function of F-box protein 11 (FBXO11), an E3 ubiquitin ligase, in the development of pancreatic cancer (PCa). Differentially expressed genes in PCa were identified using the GSE62452 and GSE28735 datasets, and FBXO11 was significantly highly expressed in PCa. UTMD-mediated FBXO11 silencing significantly suppressed growth activity, epithelial-mesenchymal transition, migration, and invasion while reduced apoptosis of PCa cells in vitro and reduced the growth and metastasis of xenograft tumors in vivo. Importantly, UTMD-mediated sh-FBXO11 showed more pronounced tumor-suppressive effects than direct administration of sh-FBXO11 alone. The potential substrates of FBXO11 as an E3 ubiquitin ligase were predicted using the Ubibrowser. TP53 was predicted and validated as a downstream substrate of FBXO11. FBXO11 induced ubiquitination and degradation of the tumor suppressor protein TP53 to induce PCa progression. In conclusion, this study suggests that silencing of FBXO11, especially that mediated by UTMD, might suppress the malignant biological behaviors of PCa cells and serve as a potential therapeutic strategy for PCa management.
© 2022. The Author(s) under exclusive licence to Japan Human Cell Society.

Entities:  

Keywords:  FBXO11; Pancreatic cancer; TP53; Ubiquitination; Ultrasound-targeted microbubble destruction

Mesh:

Substances:

Year:  2022        PMID: 35437704     DOI: 10.1007/s13577-022-00700-w

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  48 in total

Review 1.  Pancreatic cancer: yesterday, today and tomorrow.

Authors:  Daniel Ansari; Bobby Tingstedt; Bodil Andersson; Fredrik Holmquist; Christian Sturesson; Caroline Williamsson; Agata Sasor; David Borg; Monika Bauden; Roland Andersson
Journal:  Future Oncol       Date:  2016-06-01       Impact factor: 3.404

2.  SIRT1 promotes the proliferation and metastasis of human pancreatic cancer cells.

Authors:  Jianguang Jin; Zhijie Chu; Pengfei Ma; Yuanpu Meng; Yanhui Yang
Journal:  Tumour Biol       Date:  2017-03

3.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 4.  GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets.

Authors:  Krishna Sriram; Cristina Salmerón; Shu Z Wiley; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

Review 5.  Pancreatic Cancer: Pathogenesis and Diagnosis.

Authors:  Vedat Goral
Journal:  Asian Pac J Cancer Prev       Date:  2015

Review 6.  Immunotherapy and Prevention of Pancreatic Cancer.

Authors:  Alexander H Morrison; Katelyn T Byrne; Robert H Vonderheide
Journal:  Trends Cancer       Date:  2018-04-30

7.  Downregulation of circular RNA circ-LDLRAD3 suppresses pancreatic cancer progression through miR-137-3p/PTN axis.

Authors:  Jun Yao; Ce Zhang; Yanfei Chen; Shegan Gao
Journal:  Life Sci       Date:  2019-09-12       Impact factor: 5.037

Review 8.  Challenges in diagnosis of pancreatic cancer.

Authors:  Lulu Zhang; Santosh Sanagapalli; Alina Stoita
Journal:  World J Gastroenterol       Date:  2018-05-21       Impact factor: 5.742

Review 9.  Epidemiology of pancreatic cancer.

Authors:  Milena Ilic; Irena Ilic
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

10.  UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.

Authors:  Lizhou Lin; Yu Fan; Feng Gao; Lifang Jin; Dan Li; Wenjie Sun; Fan Li; Peng Qin; Qiusheng Shi; Xiangyang Shi; Lianfang Du
Journal:  Theranostics       Date:  2018-02-14       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.